358: FDA's gene therapy turmoil, and an alternative model for funding research
The Readout Loud
00:00
Intro
This chapter explores the aftermath of the tragic deaths of two boys from Duchenne muscular dystrophy who underwent gene therapy, raising critical questions about regulatory practices and the FDA's drug review voucher program. The conversation also addresses the growing influence of private equity in financing medical research amidst dwindling government support.
Transcript
Play full episode
